Publications by authors named "O Filhol"

Approximately one-third of advanced renal cell carcinoma (RCC) patients develop osteolytic bone metastases, leading to skeletal complications. In this review, we first provide a comprehensive perspective of seminal studies on bone metastasis of RCC describing the main molecular modulators and growth factor signaling pathways most important for the RCC-stimulated osteoclast-mediated bone destruction. We next focus on newer developments revealing with in-depth details, the bidirectional interplay between renal cancer cells and the immune and stromal microenvironment that can through epigenetic reprogramming, profoundly affect the behaviors of transformed cells.

View Article and Find Full Text PDF

Although the involvement of protein kinase CK2 in cancer is well-documented, there is a need for selective CK2 inhibitors suitable for investigating CK2 specific roles in cancer-related biological pathways and further exploring its therapeutic potential. Here, we report the discovery of AB668, an outstanding selective inhibitor that binds CK2 through a bivalent mode, interacting both at the ATP site and an allosteric αD pocket unique to CK2. Using caspase activation assay, live-cell imaging, and transcriptomic analysis, we have compared the effects of this bivalent inhibitor to representative ATP-competitive inhibitors, CX-4945, and SGC-CK2-1.

View Article and Find Full Text PDF
Article Synopsis
  • Researchers aim to extend human healthspans by keeping cells functional and non-senescent, as aging appears to be genetically regulated in model organisms.
  • A new human genetic disease linked to GIMAP5 deficiency leads to cell senescence, liver and immune dysfunction, and early death, highlighting GIMAP5's importance in longevity.
  • GIMAP5 helps regulate the accumulation of harmful long-chain ceramides by interacting with a protein kinase (CK2), and targeting CK2 can restore function in GIMAP5-deficient cells, showing its role in maintaining immune health and longevity.
View Article and Find Full Text PDF

Selenium 0 (Se) is a powerful anti-proliferative agent in cancer research. We investigated the impact of sub-toxic concentrations of Se functionalized nanoparticles (SeNPs) on prostate cancer PC-3 cells and determined their intracellular localization and fate. An in-depth characterization of functionalized selenium nanoparticles composition is proposed to certify that no chemical bias relative to synthesis issues might have impacted the study.

View Article and Find Full Text PDF